GLP-1 agonists to be among 15 drugs subject to Medicare price negotiations
-
@jon-nycChatGPT, that's a good summary.No question, in my mind, that larger portions and overall increased caloric intake are major driving forces. People have been talking about HFCS as being a problem for a long time. Is there any science that processed foods and HFCS are drivers of obesity by themselves? Or are they part of the portion and calorie stuff.
I remember reading how much sugar is in something we thought of as "healthy" - Cheerios, I believe. The amount of sugar and salt in it was amazing.
I saw a story that one fast food chain - In-And-Out? - was switching to beef tallow for their french fries.
"Now look here, you Baltic gas passer... " - Mik, 6/14/08
The saying, "Lite is just one damn thing after another," is a gross understatement. The damn things overlap.
-
@jon-nycChatGPT, that's a good summary.No question, in my mind, that larger portions and overall increased caloric intake are major driving forces. People have been talking about HFCS as being a problem for a long time. Is there any science that processed foods and HFCS are drivers of obesity by themselves? Or are they part of the portion and calorie stuff.
I remember reading how much sugar is in something we thought of as "healthy" - Cheerios, I believe. The amount of sugar and salt in it was amazing.
I saw a story that one fast food chain - In-And-Out? - was switching to beef tallow for their french fries.
@George-K said in GLP-1 agonists to be among 15 drugs subject to Medicare price negotiations:
I saw a story that one fast food chain - In-And-Out? - was switching to beef tallow for their french fries.
McDonalds did that for years. Wonder if they'll switch back?
-
And channeling RFK would be to outline a nanny-state plan to ban unhealthy foods and perfectly fine foods about which I’ve contrived conspiracy theories.
@jon-nyc said in GLP-1 agonists to be among 15 drugs subject to Medicare price negotiations:
a nanny-state plan to ban unhealthy foods and perfectly fine foods about which I’ve contrived conspiracy theories.
I'd rather see some people die young from eating unhealthy food.
The Nanny-state is bad, even when it protects us from real danger.
Of course we have to be informed, beyond that it is none of the government's business.
Now, who wants to pay for healthcare for all those fat people?
-
Norm...
Link to video -
Me: What’s the next generation of weight loss drugs after GLP-1 agonists.
ChstGPT:
The landscape of weight loss medications is rapidly evolving beyond traditional GLP-1 receptor agonists, with several promising developments on the horizon:
-
Multi-Receptor Agonists:
• Dual and Triple Agonists: Pharmaceutical companies are developing drugs that target multiple receptors to enhance weight loss efficacy. For instance, Eli Lilly’s retatrutide is a “triple G” agonist that activates GLP-1, GIP, and glucagon receptors. In mid-stage trials, participants achieved up to 24.2% weight loss over 48 weeks, marking significant progress in obesity treatment.  -
Amylin Analogues:
• Amylin-Based Therapies: Drugs like cagrilintide and petrelintide mimic the hormone amylin, which promotes a feeling of fullness after eating. These therapies offer an alternative mechanism to existing GLP-1-based treatments and have shown promise in early trials.  -
Oral GLP-1 Receptor Agonists:
• Convenient Pill Forms: Efforts are underway to develop effective oral GLP-1 receptor agonists. Eli Lilly’s orforglipron and Pfizer’s danuglipron are notable examples, aiming to provide the benefits of GLP-1 therapies without the need for injections.  -
Novel Targets and Mechanisms:
• NK2R Agonists: Researchers at the University of Copenhagen, funded by Novo Nordisk, have identified the neurokinin 2 receptor (NK2R) as a potential target for weight loss drugs. Early studies suggest that NK2R agonists can decrease appetite and increase calorie burning without causing nausea, a common side effect of current treatments. Clinical trials are anticipated to begin within a year, with potential public availability in five to six years. 
These advancements reflect a concerted effort to develop more effective, convenient, and tolerable weight loss medications, addressing the diverse needs of individuals seeking obesity treatment.
@jon-nyc said in GLP-1 agonists to be among 15 drugs subject to Medicare price negotiations:
Me: What’s the next generation of weight loss drugs after GLP-1 agonists.
ChstGPT:
- Multi-Receptor Agonists:
• Dual and Triple Agonists: Pharmaceutical companies are developing drugs that target multiple receptors to enhance weight loss efficacy. For instance, Eli Lilly’s retatrutide is a “triple G” agonist that activates GLP-1, GIP, and glucagon receptors. In mid-stage trials, participants achieved up to 24.2% weight loss over 48 weeks, marking significant progress in obesity treatment. 
-
